Understand this story
Anthropic's life sciences team has established research collaborations with six institutions—Generate Biomedicines, Divergence Labs, BigHat Biosciences, Enveda, The Column Group, and Bristol Myers Squibb—to jointly develop new drugs, while also acquiring Mithril Medicine, a biotechnology company independently operated by Cody Tranbarger, to directly conduct drug research and development. Anthropic says Claude has already delivered quantifiable improvements in molecular design, manufacturing document review, regulatory filings, and clinical trial planning; for example, Enveda used Claude to review 1,061 pages of documents, identifying all 11 issues found by humans and flagging 7 additional ones, cutting manual review time from more than 25 hours to less than 3 hours. Anthropic says it plans to significantly expand this work, and if candidate drugs perform well, it expects to be ready to launch human clinical trials as early as the end of 2028.
AI-generated from public reports
Latest development · Report
October 28 AI Daily Brief: Genie 4 and MAI-Image-2.7 ReleasedDevelopments
1 confirmed developments
Anthropic partners with six institutions to advance drug discovery
Source:Wallstreetcn
Reports and discussion timeline
Browse reports and discussion by time. Their evidence levels remain distinct.
Oct 28
Testing Catalog
October 28 AI Daily Brief: Genie 4 and MAI-Image-2.7 Released
Google DeepMind released the interactive world model Genie 4, which supports natural language control and native audio. It is first being opened to Trusted Testers, with later integration into Google AI Ultra and the Gemini API. Microsoft AI launched the image editing model MAI-Image-2.7-Preview, ranking 3rd on Arena Edit and 2nd on AA-Image-Editing. Liquid AI open-sourced the LFM3 series of six 2B-class text, vision, audio, and omni-modal models, using a triple-hybrid architecture.
Yicai
Anthropic Acquires One-Person Pharma Company Mithril Medicine, AI Giants Rush into the Pharmaceutical Industry
On October 27, Anthropic disclosed the acquisition of Mithril Medicine, a biotechnology company with only one full-time employee. Its founder used Claude to coordinate 11 external laboratories and, in less than 18 months, advanced a candidate therapy for a rare muscular dystrophy to mouse experiments with preliminary positive results. Anthropic also disclosed collaborations with six institutions including Bristol Myers Squibb and Generate Biomedicines, covering molecular design, experimental optimization, drug manufacturing, and clinical trial planning, and has listed life sciences as an important application market for frontier AI in its prospectus. OpenAI announced on October 20 the acquisition of drug R&D collaboration platform Orchestra Bio, Google's Isomorphic Labs is collaborating with Eli Lilly and Novartis, and Anew Labs, spun off from ByteDance, is said to have completed approximately $290 million in financing.
WallstreetcnSelected
Anthropic acquires one-person pharma company Mithril Medicine and partners with six institutions to advance AI drug discovery
Anthropic's life sciences team has established research collaborations with six institutions—Generate Biomedicines, Divergence Labs, BigHat Biosciences, Enveda, The Column Group, and Bristol Myers Squibb—and has acquired Mithril Medicine, a biotech company independently run by Cody Tranbarger, to directly conduct drug R&D. Anthropic says Claude has delivered quantifiable improvements in molecular design, manufacturing document review, regulatory filings, and clinical trial planning; for example, Enveda used Claude to review 1,061 pages of documents, which identified all 11 issues found by humans and flagged 7 additional ones, cutting manual review time from over 25 hours to under 3 hours. Anthropic says it plans to significantly scale up this work, and if the candidate drugs perform well, it expects to be ready to begin human clinical trials as early as the end of 2028.
Oran GeRelated discussion
Oran Ge joined this discussion
This post contributes to heat; it is not a formal report or confirmed fact.
@mark_kRelated discussion
@mark_k joined this discussion
This post contributes to heat; it is not a formal report or confirmed fact.
Rohan Paul
Anthropic says Claude has been used in real drug programs at 6 companies
Anthropic said that over the past few months, its scientists have established deep research partnerships with 6 organizations developing new medicines, while also launching its own drug discovery efforts. Claude's work went beyond proposing molecular ideas: it generated about 35,000 antibody designs in roughly one month, coordinated 11 external laboratories for a one-person biotech company, and identified 7 production issues that human reviewers had missed. Most of this work is still at the preclinical stage, and one drug in Anthropic's own program could enter human trials as early as the end of 2028.
BaoyuRelated discussion
Baoyu joined this discussion
This post contributes to heat; it is not a formal report or confirmed fact.
Unite.AI
Anthropic Publishes Early Progress of Claude in Drug Discovery
On October 27, 2026, Anthropic released a life sciences progress update, disclosing early results from collaborations with six institutions—BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group—as well as its first in-house drug program. Six scientists at Generate used Claude Code to build an agent system and selected candidates from 186 CAR T cell therapy signaling domain redesigns; one design was about 70% shorter than the standard version, and in laboratory tests the number of cell surface receptors was about 10 times the original. Divergence Labs said Claude generated about 35,000 antibody designs under about 2,750 hours of H100 compute, and 20 of the 91 tested disruptor designs measurably stripped already-bound IgE. Enveda used Claude to review 1,061 pages of production batch records, reducing review time from 25.9 hours to 2.8 hours, and said drafting Module 2 of an investigational new drug application was shortened from about three months to four hours. Anthropic emphasized that these results are still early, mostly preclinical, and safety and efficacy have not yet been validated in patients.
Anthropic
Anthropic Partners with Six Drug Discovery Organizations and Launches Its Own Drug Discovery Project
Anthropic said that over the past few months, its scientists have established deep research collaborations with six organizations developing new drugs, while the company has also launched its own drug discovery work. Anthropic said this has given it a better understanding of what support Claude can provide across multiple stages of drug development, and it shared early results from this work and the company's overall plans in the life sciences in a blog post.
Oct 27
Hacker News Trending
Anthropic Uses Claude to Accelerate Drug Discovery: Partners with Six Institutions and Launches Its Own Drug Discovery Program
Anthropic's life sciences team is collaborating with six institutions—BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, and The Column Group—to use Claude in supporting drug development, and has launched its own drug discovery program targeting diseases such as rare childhood muscular dystrophy. BMS uses Claude in clinical trial planning to analyze proprietary data, generate research plans, and assess success rates; a single prompt can accomplish preliminary analysis that would otherwise take several days. Most of the research is currently at the preclinical stage, and Anthropic plans to expand its collaboration with BMS in 2027.
Heat trend for this story
- Current
- 59
- Period peak
- 62 Oct 28 13:00
- 24-hour change
- —
Move the pointer or select the chart to inspect hourly heat. Use the left and right arrow keys with a keyboard.